Alvimopan
References
- Frank, Scott Alan; Prather, Douglas Edward; Ward, Jeffrey Alan; Werner, John Arnold, Preparation of 3,4,4-trisubstitutedpiperidinyl-n-alkylcarboxylates and intermediates, useful as opioid antagonists, Eli Lilly and Co., United States, EP657428B1, April 4, 2001
- You, Jun; Cai, Sheng; Wu, Shuping, Separation of alvimopan and its enantiomers by HPLC using β-cyclodextrin as chiral mobile phase additive, Zhongguo Xiandai Yingyong Yaoxue, Volume: 31, Issue: 9, Pages: 1101-1104, 2014
Frequently Asked Questions
Why is it essential to analyze Alvimopan impurities?
Analyzing impurities in Alvimopan is critical to ensure drug safety and effectiveness. The impurities can affect drug quality, stability, and safety reducing its efficacy or causing harm to patients. Analyzing impurities can help identify their sources, enabling manufacturers to control their formation.
What steps can manufacturers take to control impurity levels in Alvimopan?
Manufacturers can take various steps to control impurity levels in Alvimopan, including using high-quality starting materials, optimizing reaction conditions, implementing effective purification techniques, and monitoring impurity levels throughout the manufacturing process.
Which solvent helps in the analysis of Alvimopan impurities?
Methanol is a solvent used in analyzing many impurities in Alvimopan.
What are the temperature conditions required to store Alvimopan impurities?
Alvimopan impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.